Title :

COVID-19 presentation and outcomes in patients with inflammatory rheumatic and musculoskeletal diseases receiving IL6-receptor antagonists prior to SARS-CoV-2 infection.

Author(s) :

Comarmond, Cloé [Auteur]
Hôpital Lariboisière-Fernand-Widal [APHP]
Drumez, Elodie [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Labreuche, Julien [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Hachulla, Eric [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Thomas, Thierry [Auteur]
Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] [CHU ST-E]
Flipo, René-Marc [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Seror, Raphaëlle [Auteur]

Avouac, Jérôme [Auteur]
Hôpital Cochin [AP-HP]
Balandraud, Nathalie [Auteur]
Hôpital Sainte-Marguerite [CHU - APHM] [Hôpitaux Sud ]
Desbarbieux, Renaud [Auteur]
Centre Hospitalier Boulogne-sur-mer
Felten, Renaud [Auteur]
Centre Hospitalier Universitaire [Strasbourg] [CHU Strasbourg]
Gilson, Mélanie [Auteur]
Centre Hospitalier Universitaire [CHU Grenoble] [CHUGA]
Guyot, Marie-Hélène [Auteur]
Hôpital Victor Provo [Roubaix]
Hittinger-Roux, Ambre [Auteur]
Hôpital universitaire Robert Debré [Reims] [CHU Reims]
Pham, Thao [Auteur]
Hôpital Sainte-Marguerite [CHU - APHM] [Hôpitaux Sud ]
Renard, Myriam [Auteur]
Université Grenoble Alpes - UFR Médecine [UGA UFRM]
Roux, Nicolas [Auteur]
Centre hospitalier régional Metz-Thionville [CHR Metz-Thionville]
Sobanski, Vincent [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Tournadre, Anne [Auteur]
CHU Clermont-Ferrand
Richez, Christophe [Auteur]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Cacoub, Patrice [Auteur]
CHU Pitié-Salpêtrière [AP-HP]

Journal title :

Journal of Translational Autoimmunity

Abbreviated title :

J Transl Autoimmun

Volume number :

6

Pages :

100190

Publication date :

2023-01-24

ISSN :

2589-9090

English keyword(s) :

COVID-19
Inflammatory rheumatic and musculoskeletal
diseases
Anti-IL6

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Objective COVID-19 outcome may be less favourable in patients with inflammatory rheumatic and musculoskeletal diseases (RMD) receiving immunosuppressive therapy. We aimed to investigate whether RMD patients on anti-IL6 ...
Show more >Objective COVID-19 outcome may be less favourable in patients with inflammatory rheumatic and musculoskeletal diseases (RMD) receiving immunosuppressive therapy. We aimed to investigate whether RMD patients on anti-IL6 therapy prior to SARS-CoV-2 infection have less severe disease and better outcomes of COVID-19. Methods We conducted a retrospective national, multicentre cohort study using data from the French RMD COVID-19 cohort. We compared the severity and outcome of highly suspected or confirmed COVID-19 infection in RMD patients previously treated with tocilizumab or sarilumab (anti-IL6 group) with patients who did not receive anti-IL6 therapy (no anti-IL6 group). Results Data were collected for 1883 patients with mean age of 55.2 years [SD 16.7] and 1256 (66.7%) female. Two hundred ten (11.1%) developed severe COVID-19 and 115 (6.4%) died. After adjusting for potential confounding factors, severe COVID-19 was less frequent in the anti-IL6 group compared with the no anti-IL6 group (aOR for moderate vs. mild severity, 0.23 [95% CI, 0.10 to 0.54], p ≤ 0.01 and aOR for severe vs. mild, 0.29 [95% CI, 0.10 to 0.81], p ≤ 0.01). No significant differences were found for the evolution of COVID-19 between the anti-IL6 group and the no anti-IL6 group (aOR for recovery with sequelae vs recovery without sequelae, 0.78 [95% CI, 0.41 to 1.48] and aOR for death vs recovery without sequelae, 0.29 [95% CI, 0.07 to 1.30]). Conclusion RMD patients receiving anti-IL6 therapy prior to SARS-CoV-2 infection have less severe forms of COVID-19. No difference was observed in COVID-19 evolution, i.e., sequelae or death, between the groups.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Submission date :

2023-11-15T02:33:24Z
2024-04-05T09:13:56Z